Entia Biosciences, Inc.
ERGO
$0.0001
-$0.0001-50.00%
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Revenue | -23.44% | -50.34% | -47.62% | -45.70% | -47.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.44% | -50.34% | -47.62% | -45.70% | -47.17% |
| Cost of Revenue | -30.15% | -46.25% | -47.01% | -39.35% | -46.64% |
| Gross Profit | -19.45% | -52.69% | -47.97% | -49.31% | -47.44% |
| SG&A Expenses | -37.08% | -53.58% | -51.45% | -11.48% | -2.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.68% | -53.02% | -51.09% | -14.03% | -6.78% |
| Operating Income | 39.08% | 53.74% | 52.03% | 3.46% | -8.19% |
| Income Before Tax | 38.24% | 52.19% | 52.67% | 11.82% | 1.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.24% | 52.19% | 52.67% | 11.82% | 1.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.24% | 52.19% | 52.67% | 11.82% | 1.59% |
| EBIT | 39.08% | 53.74% | 52.03% | 3.46% | -8.19% |
| EBITDA | 38.98% | 53.99% | 51.73% | 1.45% | -10.49% |
| EPS Basic | 58.58% | 74.25% | 78.05% | 65.64% | 50.72% |
| Normalized Basic EPS | 61.06% | 75.92% | 79.20% | 66.81% | 51.52% |
| EPS Diluted | 58.58% | 74.25% | 78.05% | 65.64% | 50.72% |
| Normalized Diluted EPS | 61.06% | 75.92% | 79.20% | 66.81% | 51.52% |
| Average Basic Shares Outstanding | 23.64% | 56.09% | 108.64% | 174.19% | 141.05% |
| Average Diluted Shares Outstanding | 23.64% | 56.09% | 108.64% | 174.19% | 141.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
